Oss, The Netherlands, March 16, 2016 / B3C newswire / -- ModiQuest Research BV, the Dutch antibody services company, today announced that it will continue its collaboration with Sobi™ aimed at the generation of novel monoclonal antibodies against Sobi target(s).
During the new project, ModiQuest will screen their high class in-house phage display libraries, ModiPhage™. Financials details of the collaboration were not disclosed.
“We are delighted that Sobi has selected ModiQuest Research as antibody generation partner,” said Dr. Jos Raats, Managing Director of ModiQuest Research. “We are very much looking forward to build a long-term partnership with Sobi and to apply our unique antibody technology platform in the field of orphan diseases.”
About ModiQuest Research BV
For over 10 years ModiQuest Research specializes in the generation of monoclonal antibodies against difficult targets for R&D, diagnostic and therapeutic applications. Using our proprietary ModiVacc™ (hyper-immune stimulatory cell immunization), ModiFuse™ (electrofusion based hybridoma generation), ModiSelect™ (antigen specific B-cell selection) and ModiPhage™ (phage display) technologies, we can generate monoclonal antibodies from multiple species against virtually any target. Besides lead antibody generation, we also provide antibody development and optimization (ModiTune™), such as affinity maturation, humanization and production (ModiXpress™) in transient and stable mammalian cell systems. All services are offered on a fee-for-service basis.
